|
|
|
HUYA Bioscience International is the leader in U.S./China pharmaceutical co-development, with three strategic offices in China, the broadest Chinese compound portfolio, and more exclusive agreements with premier Chinese biotech centers than any other company. As a result of the success of its pioneering Integrated Co-development Model (ICM), HUYA has secured rights to the only Chinese compounds that have been out-licensed for development in the West. HUYA has joint headquarter offices in San Diego, California, and Shanghai, China.
HUYA’s Integrated Co-development Model The global pharmaceutical industry faces a pressing need for new untapped sources of pre-clinical and clinical stage compounds for the drug development process. HUYA was one of the first companies to recognize China’s potential to help meet this need through its burgeoning biotechnology industry and world-class talent pool. HUYA pioneered an innovative approach – the HUYA Integrated Co-development Model – for partnering with Chinese research institutions and pharmaceutical companies. HUYA identifies and licenses the most promising pre-clinical and clinical stage compounds in China, leverages and extends the research efforts of its Chinese partners, and provides a bridge into the Western development process and biopharma market. [read more]
|
|
|
